Share this article on:

Interferon-α drives monocyte gene expression in chronic unsuppressed HIV-1 infection

Rempel, Hansa; Sun, Binga; Calosing, Cyrusa; Pillai, Satish Kb,c; Pulliam, Lynna,b,c,d

doi: 10.1097/QAD.0b013e32833ac623
Basic Science

Objectives: HIV-1 infection dysregulates the innate immune system and alters leukocyte-gene expression. The objectives were two fold: to characterize the impact of HIV-1 infection on peripheral monocyte gene expression and to identify the predominant factor(s) responsible for altered gene expression.

Design and methods: In a cross-sectional study (n = 55), CD14+ monocytes were isolated from 11 HIV-1 seronegative controls, 22 HIV-1 seropositive individuals with low-viral loads (LVL) and 22 HIV-1 seropositive individuals with high-viral loads (HVL). Monocyte gene expression data were collected for control, LVL and HVL individuals using high-density microarrays. We evaluated three HIV-1 disease-related peripheral factors, interferon (IFN)-α, IFN-γ and lipopolysaccharide (LPS) as candidates causing monocyte dysregulation, by comparing gene expression profiles between study individuals and monocytes treated with these factors in vitro. Plasma from HIV-1 positive individuals was quantified for LPS and soluble CD14.

Results: Monocytes from HIV-1-infected individuals with viral loads above 10 000 RNA copies/ml (HVL) displayed an activated phenotype. Characterization of gene expression revealed an ongoing immune response to viral infection including inflammation and chemotaxis. Gene expression analysis of in-vitro-treated HIV-1 seronegative monocytes with IFN-α, IFN-γ or LPS demonstrated that IFN-α most accurately recapitulated the HIV-1 HVL profile. No LPS-induced gene expression signature was detected even in HIV-1 individuals with the highest LPS and sCD14 levels.

Conclusion: Monocyte gene expression in individuals with HIV-1 viremia is predominantly due to IFN-α, whereas individuals with LVL have a nonactivated phenotype. In monocytes, there was no discernible expression profile linked to LPS exposure.

aDepartments of Laboratory Medicine, USA

bMedicine, San Francisco Veterans Affairs Medical Center, USA

cDepartments of Medicine, USA

dLaboratory Medicine, University of California, San Francisco, California, USA.

Received 2 November, 2009

Revised 4 February, 2010

Accepted 8 April, 2010

Correspondence to Dr Lynn Pulliam, PhD, San Francisco Veterans Affairs Medical Center, USA. Tel: +1 415 221 4810 x6490; fax: +1 415 379 5647; e-mail:

Back to Top | Article Outline


HIV-1 infection severely impacts the immune system causing phenotypic changes in peripheral cells altering both innate and adaptive-immune responses. The typical consequence of untreated HIV-1 infection is AIDS resulting from direct infection of susceptible cells and indirect-immune activation [1]. Within weeks of infection, during the acute phase, HIV-1 attacks and kills CCR5-expressing CD4+ T lymphocytes in the gastrointestinal tract, which impairs the mucosal layer and integrity of the barrier function [2]. The damaged gastrointestinal tract permits the translocation of bacteria and bacterial products, including lipopolysaccharide (LPS), which is a major structural component of the outer wall of Gram-negative bacteria and is elevated in HIV-1-infected individuals [2]. Lipopolysaccharide in the plasma interacts with LPS-binding protein and subsequently binds cell surface receptor CD14 prior to transfer to the toll-like receptor 4 (TLR-4) and MD2, a secreted glycoprotein required for LPS binding to TLR-4 [3]. Peripheral blood monocytes express surface markers CD14 and TLR-4, and are activated by LPS. Elevated levels of LPS in the periphery are associated with increased soluble CD14 (sCD14) [4] and are sufficient to induce an acute-phase inflammatory response [5].

The innate immune system responds immediately following HIV-1 infection producing cytokines designed to limit viral infection and replication. Interferon-α is an early response factor whose role in HIV-1 infection remains a paradox having attributes of both disease protection and progression (review [6]). In both humans and nonhuman primates, elevated IFN-α is associated with acute HIV-1 and SIV infection, respectively [7,8]. In individuals infected with HIV-1, viral replication correlated with upregulation of type I interferon-stimulated gene expression profiles [9]. Early studies suggested a modest therapeutic effect of IFN-α by preventing CD4 cell decline and reducing the incidence of AIDS-associated opportunistic infections [10]. However, later research implicated IFN-α in spontaneous apoptosis of uninfected CD4 T cells [11], T-cell depletion [12] and disease progression [13]. In another study, the adverse effects of IFN-α were demonstrated in a HIV-infected population immunized to IFN-α where individuals with elevated anti-IFN-α antibodies experienced significantly lower rates of HIV-1-related events [14,15]. So while IFN-α effectively retards virus infection and limits virus production at the cellular level, it may be responsible for impairing the immune system and chronicimmune activation.

Monocytes are key immune responsive cells whose function is adversely impacted by HIV-1. Unlike activated CD4+ T cells, monocytes are recalcitrant to infection [16] requiring maturation to a macrophage to be highly susceptible to infection. For individuals on HAART, estimates of less than 1% of monocytes harbor replication-competent virus with no indication that infection progresses to cell death [17]. Despite low rates of infection, monocytes are impaired during viremia exhibiting diminished production of proinflammatory cytokines IL-1β, IL-6 and TNF-α [9]. Previously, we reported that microarray analysis of freshly isolated monocytes from HIV-1-infected individuals with high-viral loads (HVL, more than 10 000 RNA copies/ml) expressed an altered phenotype with macrophage markers [18].

In this study, we examined the gene expression of freshly isolated CD14+ monocytes from HIV-1-infected patients, who were either successfully treated with HAART with low-viral loads (LVL, <10 000 RNA copies/ml) or from individuals with HVL due to HAART failure or treatment interruption. Segregating the monocyte gene expression data based on individual viral load revealed an expression profile indicating that unsuppressed viremia is a significant factor impacting monocyte phenotype. As CD14+ monocytes are typically responsive to type 1 and 2 IFNs, and LPS, we evaluated the activation status of monocytes in HIV-1-infected patients by gene expression analysis. We then compared the patient monocyte gene expression profiles with expression data from HIV-1-seronegative CD14+ monocytes that were treated in vitro with IFN-α, IFN-γ or LPS. When monocyte microarray results from HVL individuals were compared with the in-vitro-treated monocytes, they displayed an IFN-α activation profile. In addition, there was no evidence of an LPS-induced gene expression profile even though LPS and sCD14 were elevated in the plasma of HIV-1-infected individuals. The implication of these findings is that IFN-α reprograms the innate immune response of monocytes and desensitizes them to normally activating microbial factors.

Back to Top | Article Outline

Materials and methods


This study was conducted with the participation of individuals recruited at the San Francisco VA Medical Center with written consent approved by the University of California, San Francisco Committee on Human Research. Global gene expression analysis using high-density cDNA microarrays was performed on CD14+ monocytes isolated from 55 individuals, 22 with HIV-1 HVL, 22 with HIV-1 LVL and 11 HIV-1 seronegative controls. The categorization of high or low-viral load was based on clinical criteria with LVL less than 10 000 RNA copies/ml and HVL as more than 10 000 RNA copies/ml. The LVL group included 14 individuals with undetectable viral loads (<50 RNA copies/ml). Individuals in the study were males between 30 and 66 years of age with the mean age for control individuals being 53 years ± 4.1 (± SD), the mean age of LVL individuals being 51 years ± 8.3 and the mean age of HVL individuals being 50 years ± 7.7. The cohort was comprised of white (62%), black (19%), Hispanic (12%), Asian (4%) and other (3%) individuals. At the time of the study, individuals in the LVL group were on HAART, whereas individuals with HVL were in one of three categories on HAART (n = 15); scheduled treatment interruption (n = 6) or HAART naive (n = 1). When monocytes were isolated for gene expression analysis, median CD4 cell counts for the groups were controls = 1038 cells/μl; LVL = 429 cell/μl and HVL = 123.5 cell/μl and a Student's t-test revealed a statistically significant difference in CD4 cell counts between LVL and HVL (P = 0.0015). No significant difference was detected in median nadir CD4 cell counts between LVL = 146.5 cells/μl and HVL = 52.5 cells/μl (P = 0.187).

Back to Top | Article Outline

Isolation of CD14+ monocytes

Whole blood was drawn into Vacutainer CPT tubes (BD, Franklin Lakes, New Jersey, USA) and peripheral blood mononuclear cells (PBMC) were enriched by centrifugation at 1600g for 25 min [18]. CD14+ monocytes were positively selected from PBMC immunomagnetic separation using anti-CD14 monoclonal antibodies conjugated to ferrous beads according to the manufacturer's instructions (Miltenyi Biotech, Auburn, California, USA). On average, 3 × 106 CD14+ monocytes were isolated from 30 ml of whole blood. Monocyte purity exceeded 97% with less than 1% contaminating T or B cells as determined by flow cytometry (data not shown).

Back to Top | Article Outline

In vitro stimulation of monocytes

Monocytes for in-vitro experiments were isolated from HIV-1 seronegative healthy donors (Blood Centers of the Pacific, San Francisco, California, USA). In brief, cells were flushed from leukoreduction filters with 40 ml PBS (Ca2+ and Mg2+-free) and monocytes (5× 106 cells/filter) were CD14 positively selected by immunomagnetic separation. CD14+ cells were treated with 50 U/ml IFN-α2a (PBL Biomedical Laboratories, Piscataway, New Jersey, USA), 100 U/ml IFN-γ (R&D Systems, Minneapolis, Minnesota, USA) or 1 ng/ml LPS obtained from E. coli 0127:B8 (Sigma, St Louis, Missouri, USA) in RPMI-1640 supplemented with 10% FBS, 1.0 μg/ml gentamicin and 2 mmol/l L-glutamine at 37°C and 5% CO2 for 48 h in Costar Ultra Low Attachment plates (Corning, Lowell, Massachusetts, USA).

Back to Top | Article Outline

RNA isolation and monocyte gene expression analysis

Total RNA was isolated from monocytes using the RNeasy Micro Kit (Qiagen, Valencia, California, USA). RNA integrity was evaluated on the Agilent Bioanalyzer 2100 using a RNA 6000 Pico LabChip (Agilent Technologies, Palo Alto, California, USA) and all samples had a RIN value exceeding eight [19]. Complementary RNA (cRNA) was synthesized and labeled with biotin using iExpress iAmplify kit (Applied Microarrays, Tempe, Arizona, USA). cRNA was hybridized to Codelink Whole Human Genome Bioarrays (55K probes, Applied Microarrays). The hybridization signal was acquired on an Axon GenePix 4000B scanner (Molecular Devices, Sunnyvale, California, USA) and image analysis and data extraction were performed by CodeLink Expression Software Kit v4.1 (Applied Microarrays). Gene expression data for the HIV-1-infected individuals and HIV-1-seronegative individuals are available at NCBI GEO database, accession number GSE18464.

Microarray data were normalized with loess normalization using R [20] and Bioconductor package [21]. Determination of differential gene expression significance and multiple testing correction/false discovery rate adjustments [22] were performed using GeneSpring GX 7.3 software package (Agilent). Gene ontology analysis ( was conducted using the GeneSpring GX software package. Correlations between in-vitro and in-vivo gene expression patterns were evaluated using multiple nonparametric tests within the GraphPad Prism v5.0b Statistical Analysis Software Package.

Back to Top | Article Outline

Plasma lipopolysaccharide and sCD14

LPS levels in individual plasma were quantified using the Pyrogene Recombinant Factor C Endotoxin Detection System (Lonza, Walkersville, Maryland, USA) according to manufacturer's protocol. Briefly, plasma samples were diluted 1: 50 in pyrogen-free water before incubation with rFC working reagent. Fluorescence was measured at time zero and again at 1 h with a SpectroMax microplate reader and endotoxin concentrations were determined using a standard curve. Soluble CD14 levels in plasma samples were quantified by ELISA with the Quantikine Human sCD14 Immunoassay (R&D Systems, Minneapolis, Maryland, USA) according to the manufacturer's protocol. Samples were assayed in triplicate.

Back to Top | Article Outline


High-HIV-1 viral load induces an activated monocyte phenotype

HIV-1 infection radically alters the monocyte phenotype, which is reflected in an HIV-1-induced gene expression profile. To characterize the monocyte transcriptome during HIV-1 infection, global gene expression analysis using high-density cDNA microarrays was performed on cells isolated from 44 HIV-1-seropositive individuals and 11 HIV-1 seronegative controls. HIV-1-seropositive individuals were subdivided into two groups based on a clinical definition of viral load status with 22 individuals with LVL (<10 000 RNA copies/ml) and 22 individuals with HVL (>10 000 RNA copies/ml). Monocyte gene expression in the LVL group compared with controls identified one gene that met the threshold of differential expression (DE) (≥two-fold upregulated or downregulated with a P ≤ 0.05 as determined by Student's t-test following correction for multiple comparison). The number of DE genes were increased to 139 for HVL vs. control and there were 99 DE genes for HVL vs. LVL. (Gene list with fold change for HVL vs. LVL, HVL vs. controls and LVL vs. controls in supplemental data 1,

Back to Top | Article Outline

Chronic immune activation correlates with HIV-1 viremia

Although the interplay between HIV-1 and the immune system has been extensively studied (review [1]), dysregulation of circulating monocytes has received little attention. To characterize monocyte dysfunction, we developed a chronic immune activation (CIA) index based on a limited number of genes elevated in HIV-1-infected individuals. The index is comprised of 19 genes that are related to immune activation and are upregulated three to 54-fold in HIV-1-infected individuals including those with undetectable viral loads, which were arbitrarily assigned 50 RNA copies/ml (Fig. 1a). Subclassification of gene function includes signal transduction, inflammatory response and chemotaxis (Fig. 1b). To generate a CIA value for each individual, the mean intensity of all 19 genes were taken for each sample and calculated as follows:

Fig. 1

Fig. 1



where intensity equals corrected and normalized signal intensity for each gene and n equals the 19 selected genes. For each individual, the CIA value and corresponding viral load were plotted, and linear regression analysis showed a Pearson's coefficient of R 2 = 0.715 with P < 0.0001 (Fig. 1c). Correlation between CIA and log viral load indicates that the CIA index can be used to define monocyte activation in HIV-1-infected individuals (Fig. 1c).

Back to Top | Article Outline

IFN-α drives CD14+ monocyte gene expression in HIV-1 high-viral load individuals

Of numerous secreted factors that are present in the plasma and characterized as inducers of monocyte gene expression, IFN-α, IFN-γ and LPS have been shown to be elevated in HIV-1-infected individuals. To determine which of these factors was principally responsible for driving monocyte gene expression in the periphery, we treated freshly isolated CD14+ monocytes obtained from three healthy HIV-1-seronegative individuals with IFN-α, IFN-γ or LPS for 48 h. Monocyte RNA was analyzed with the same 55K high-density microarrays that were used for the HIV-1 patient samples. From each CD14+ monocyte preparation, one untreated and three treated (IFN-α, IFN-γ or LPS) cultures were harvested and analyzed for gene expression. Following the same DE criteria used for patient monocytes (≥2-fold upregulated or downregulated with a P ≤ 0.05 as determined by Student's t-test following correction for multiple comparison), IFN-α-treated cultures had 224 DE genes; IFN-γ-treated cultures had 107 DE genes and LPS, 992 DE genes (Fig. 2a). To present these results from the patient monocyte perspective, the heat map for control, LVL and HVL individuals illustrates the induced HVL profile and the genes in each in-vitro culture that are similarly expressed (Fig. 2b). Of the various treatments, IFN-α produced an expression profile exhibiting the highest concordance with 49 genes that were also expressed in the patient HVL monocytes. Of the 107 DE genes in the IFN-γ-treated cultures, there were only three unique genes expressed in common with the HVL group. For LPS, only one gene was similarly regulated in the HVL group.

Fig. 2

Fig. 2

Although the heatmap (Fig. 2a) illustrates that HVL and IFN-α create overlapping monocyte expression profiles, further analysis was required to demonstrate that IFN-α was indeed a factor driving monocyte gene expression in HVL individuals. We first sought to determine that the number of DE genes shared by both IFN-α and HVL status was statistically significant. High-density microarrays in these experiments have 54 936 probes of which 96 genes were DE by the HVL group and 224 genes were DE following IFN-α treatment. There were 49 DE genes in common between HVL and IFN-α-treated monocytes (Fig. 3a). Chi-squared analysis revealed a highly significant association between the sets of DE genes in these two groups (P < .0001). We next investigated whether genes upregulated in the HVL group were elevated in the same hierarchical rank order in the IFN-α-treated monocytes. Using the Spearman's rank test (a conservative nonparametric measurement of correlation), the correlation in gene expression levels between HVL and IFN-α treatment was found to be highly significant (r = 0.789, P < 0.0001). Even when two of the highest expressed genes were deleted from the analysis (IF127, Sn), the relationship remained significant (r = 0.755, P < 0.0001) (Fig. 3b).

Fig. 3

Fig. 3

Back to Top | Article Outline

Lipopolysaccharide and sCD14 are elevated in plasma of HIV-1-infected individuals with high viral loads

The absence of an LPS-associated gene expression profile in HVL individuals was curious as monocytes treated in vitro with LPS exhibited a significant gene response and there are numerous reports of elevated LPS levels in the periphery during HIV-1 infection [2,16,23]. To specifically evaluate our cohort, we assayed patient plasma samples reserved from the PBMC/CD14+ monocyte isolations and found a significant increase in LPS concentration in both LVL and HVL compared with controls (Fig. 4a). To confirm the LPS results, we assayed plasma samples for sCD14, which has been shown to be a marker with high-correlative value for LPS [4]. Similar to LPS, mean sCD14 levels increased significantly between controls and HIV-1 LVL, and between LVL and HVL (Fig. 4b). These two assays clearly demonstrate elevated LPS in the periphery and similar to IFN-α-induced gene expression, LPS increased with viral load.

Fig. 4

Fig. 4

To resolve the apparent inconsistency between elevated LPS levels in the periphery and absence of any LPS-induced gene expression in HVL individuals, genes known to be upregulated in the LPS-treated monocytes were specifically queried in the HVL data set. Four genes, CXCL3, IL-10, IL-6 and IL-1β were selected because they were significantly elevated in the LPS-treated monocytes and have been described in the literature as regulated by LPS [3,24] (Table 1). In all three group comparisons, HVL/C, HVL/LVL and LVL/C, there was no significant increase in expression, not even a trend. These results suggest that circulating monocytes are desensitized to LPS found in the plasma of HIV-1-infected individuals.

Table 1

Table 1

Back to Top | Article Outline


Our data provide detailed information on the effect of chronic HIV-1 infection on the gene expression profile of circulating CD14+ monocytes. Global gene expression of peripheral monocytes was determined immediately following isolation from infected and control individuals thus providing accurate representation of the status of peripheral cells that play a critical role in innate immunity. Gene expression analysis revealed that maintaining a low-viral load through effective HAART treatment resulted in a monocyte expression profile similar to that of HIV-1-seronegative controls. In contrast, HIV-1-infected individuals with high-viral loads (>10 000 RNA copies/ml) had an average of 139 DE genes. The predominant characteristic of the monocyte profile was the number of type I IFN-regulated genes with expression intensities that correlated with viral load. Although our findings confirm the report by Tilton et al. [9] of an elevated type I interferon monocyte gene expression profile in individuals with HVL, we provide new evidence that IFN-α is the primary driver of gene expression during viremia. Previously, we identified a number of genes elevated in CD14+ monocytes from HIV-1-infected individuals and found that genes upregulated in individuals with high-viral loads were characteristic of an activated macrophage phenotype [18].

Peripheral monocytes in HIV-1-infected individuals with HVL have a gene expression pattern that is characteristic of chronic immune activation. We have defined the gene expression profile as the CIA index, which reflects the chronic activation state of monocytes in HIV-1-infected individuals with HVL. In both humans and nonhuman primates, elevated IFN-α was associated with acute HIV-1 and SIV infection, respectively [7,8] and in the chronic HIV-1 infection phase, serum IFN-α levels correlated with disease progression and diminished benefit from antiretroviral therapy [25]. HIV-1 stimulates plasmacytoid dendritic cell (pDC) production of IFN-α through activation of TLR-7 and TLR-9, which recognize single stranded viral RNA and unmethylated CpG-rich DNA, respectively [26,27]. pDC are the primary source of IFN-α in HIV-1 infection [28], producing up to 1000-fold more IFN than other cell types [29]. Although high-viral load generally equates with elevated expression of IFN-α responsive genes, there are individuals with high-viral loads that exhibit below average expression of IFN responsive genes. This may be due to a loss of IFN-α-producing pDC through either cell death [30], migration to lymph nodes [31] or alternatively through decreased monocyte sensitivity to IFN-α stimulation [32]. Despite these mechanisms, which in combination would reduce the number of pDC in the periphery and dampen monocyte response to IFN-α, the majority of HVL individuals retain an IFN-α-induced phenotype. It will be important to track monocyte activation and pDC populations longitudinally to understand how these variables affect disease progression.

Although the IFN-γ-treated cultures share a considerable number of DE genes in common with HVL, it is important to note that genes in this treatment group were also DE genes in the IFN-α treatment group. As type I and II IFNs share intracellular signaling pathways and therefore activate a number of genes in common, designating DE genes in the IFN-γ column as exclusively IFN-γ-induced genes is questionable. There were only three unique IFN-γ-induced genes expressed in common with the HVL group. Therefore, without additional evidence, it is reasonable to assume the majority of DE genes in the HVL group were induced by IFN-α and not IFN-γ. This assessment is supported by a study that tracked plasma IFN-α and IFN-γ levels in asymptomatic and symptomatic HIV-1-infected individuals following HAART [25]. Individuals with symptomatic HIV-1 infection had the highest IFN-α levels, whereas asymptomatic individuals had significantly lower levels albeit above controls. Furthermore, suppression of virus replication by HAART decreased IFN-α levels whereas nonresponders to HAART retained elevated IFN-α levels. In these same individuals, IFN-γ levels remained low regardless of HAART treatment and were not different from controls [25].

Lipopolysaccharide entering the periphery through a dysfunctional gastrointestinal tract damaged by T-cell decimation has been proposed as the principal factor in chronicimmune activation [2,33]. Bacterial LPS is a powerful activator of monocytes and other immune active cells that express CD14 and TLR-4. Our in-vitro results clearly demonstrate the capacity of CD14+ monocytes to respond to LPS with over 992 DE genes following a single dose of ultra-pure, E. coli-derived LPS. However, there was no LPS gene expression profile in monocytes isolated from individuals with HVL. In fact, only one LPS-related gene was differentially regulated in common with the HVL profile. Lipopolysaccharide in the periphery was confirmed by detection of both LPS and a correlative marker, sCD14, where both were significantly elevated in individuals with HVL. Considering the possibility that individual monocytes responded to LPS but did not exceed the threshold set for differential gene expression, we examined a number of genes that are characterized as LPS responsive genes that were significantly elevated in the LPS-treated monocytes. None of these genes showed an increase in expression despite multifold increases in the in-vitro-treated monocytes. A possible interpretation is that long-term exposure to suboptimal doses of LPS has produced a deactivated state rendering the monocytes nonresponsive to bacterial products [34]. Our findings indicate that CD14+ monocytes, which would be expected to respond vigorously to systemic LPS, are at minimum desensitized and are not contributing to the immune activation observed in HIV-1 disease. In fact, our observations are consistent with other reports indicating that viral load and not LPS is responsible for chronic immune activation [4,23]. Future work should be directed at identifying LPS-responsive cells in vivo that may be responsible for chronicimmune activation.

Our data suggests that IFN-α in plasma of HVL individuals has a profound impact on monocytes, which is significant because it alters monocyte function and possibly dysregulates normal monocyte maturation into macrophages and dendritic cell. We have studied one of the HVL genes, sialoadhesin (Sn), showing its expression correlated with HIV-1 viral load and was inducible by both IFN-α and IFN-γ in vitro [35]. In HIV-1 disease, Sn is induced to high levels shortly after infection and remains elevated during disease progression [36]. Sialoadhesin is a large 190 kDa transmembrane protein thought to mediate cell–cell interaction through binding of Neu5Ac sialic acids on adjacent cells [37] and we have demonstrated the capacity of Sn to effect HIV-1 trans infection of susceptible cells [35]. Upregulating this single gene has multiple consequences ranging from enhanced cell–cell interactions to increased infectivity with possible implications for immune activation. Considering the potential for an expanded role of IFN-α-induced monocytes in HIV-1 disease progression, accurate characterization of the IFN-α-induced disease phenotype will prove critical in assessing the role of these dynamic cells.

Back to Top | Article Outline


The authors thank Sandy Charles RN, Linda Adams RN and Harry Lampiris MD for recruiting individuals into this study and collecting clinical information. This research was supported by a grant from the National Institutes of Health (NIMH) R01MH073478.

H.R. undertook study design, experimental management, data analysis and interpretation and manuscript preparation. B.S. conducted data analysis and technical assistance. C.C. worked for technical assistance and manuscript preparation. S.K.P. carried on data analysis and interpretation and L.P. also worked on data analysis and interpretation and manuscript preparation.

Back to Top | Article Outline


1. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471–484.
2. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–1371.
3. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13:85–94.
4. Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, et al. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS 2009; 23:369–375.
5. Suffredini AF, Hochstein HD, McMahon FG. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179:1278–1282.
6. Herbeuval JP, Shearer GM. HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 2007; 123:121–128.
7. von Sydow M, Sonnerborg A, Gaines H, Strannegard O. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991; 7:375–380.
8. Khatissian E, Tovey MG, Cumont MC, Monceaux V, Lebon P, Montagnier L, et al. The relationship between the interferon alpha response and viral burden in primary SIV infection. AIDS Res Hum Retroviruses 1996; 12:1273–1278.
9. Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, et al. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 2006; 80:11486–11497.
10. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112:805–811.
11. Rodriguez B, Lederman MM, Jiang W, Bazdar DA, Garate K, Harding CV, et al. Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. AIDS 2006; 20:1379–1389.
12. Sedaghat AR, German J, Teslovich TM, Cofrancesco J Jr, Jie CC, Talbot CC Jr, et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 2008; 82:1870–1883.
13. Francis ML, Meltzer MS, Gendelman HE. Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Res Hum Retroviruses 1992; 8:199–207.
14. Zagury D, Lecoq H, Gervi I, Le Buanec H, Zagury JF, Bizzini B, et al. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum: an adjuvant to antiretroviral tritherapy. Biomed Pharmacother 1999; 53:90–92.
15. Gringeri A, Musicco M, Hermans P, Bentwich Z, Cusini M, Bergamasco A, et al. Active antiinterferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1: infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:358–370.
16. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE 2008; 3:e2516.
17. Sonza S, Maerz A, Deacon N, Meanger J, Mills J, Crowe S. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J Virol 1996; 70:3863–3869.
18. Pulliam L, Sun B, Rempel H. Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load. J Neuroimmunol 2004; 157:93–98.
19. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006; 7:3.
20. Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. J Comput Graph Stat 1996; 5:299–314.
21. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5:R80.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B (Methodological) 1995; 57:125–133.
23. Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM, Goodier MR. Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individuals. AIDS 2009; 23:29–34.
24. Goodall JC, Ellis L, Yeo GS, Gaston JS. Does HLA-B27 influence the monocyte inflammatory response to lipopolysaccharide? Rheumatology (Oxford) 2007; 46:232–237.
25. Stylianou E, Aukrust P, Bendtzen K, Muller F, Froland SS. Interferons and interferon (IFN)-inducible protein 10 during highly active antiretroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol 2000; 119:479–485.
26. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5:1219–1226.
27. Zhang Z, Wang FS. Plasmacytoid dendritic cells act as the most competent cell type in linking antiviral innate and adaptive immune responses. Cell Mol Immunol 2005; 2:411–417.
28. Lehmann C, Harper JM, Taubert D, Hartmann P, Fatkenheuer G, Jung N, et al. Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J Acquir Immune Defic Syndr 2008; 48:522–530.
29. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000; 192:219–226.
30. Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98:906–912.
31. Malleret B, Maneglier B, Karlsson I, Lebon P, Nascimbeni M, Perie L, et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 2008; 112:4598–4608.
32. Hardy GA, Sieg SF, Rodriguez B, Jiang W, Asaad R, Lederman MM, et al. Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. Blood 2009; 113:5497–5505.
33. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749–759.
34. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 2003; 100:171–194.
35. Rempel H, Calosing C, Sun B, Pulliam L. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS ONE 2008; 3:e1967.
36. van der Kuyl AC, van den Burg R, Zorgdrager F, Groot F, Berkhout B, Cornelissen M. Sialoadhesin in (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS ONE 2007; 2:e257.
37. Crocker PR, Mucklow S, Bouckson V, McWilliam A, Willis AC, Gordon S, et al. Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells with 17 immunoglobulin-like domains. EMBO J 1994; 13:4490–4503.

gene expression; HIV-1; IFN-α; lipopolysaccharide; monocyte

Supplemental Digital Content

Back to Top | Article Outline
© 2010 Lippincott Williams & Wilkins, Inc.